Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206285 | 0.91 | BTK (0.47) | CDK9GRM5GAAKMT2AMEN1 | |
| SCHEMBL20206287 | 0.91 | BTK (0.47) | CDK9GRM5GAAKMT2AMEN1 | |
| SCHEMBL30165290 | 0.91 | BTK (0.47) | CDK9GRM5GAAKMT2AMEN1 | |
| SCHEMBL23860696 | 0.87 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL23860700 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30165320 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30736107 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL30165323 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL26991102 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL20206222 | 0.81 | ACKR3 (0.47) | NPC1RAB9AALDH1A1TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043405-A1 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | DANA-FARBER CANCER INSTITUTE, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4125895-A1 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | Dana-Farber Cancer Institute, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043405-A1 | POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 | IRAK1, IRAK2, IRAK3 | NPC1 1194/4885RAB9A 2952/4885SMN1; SMN2 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.